These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 25326817)

  • 1. Manufactured nanomaterials: categorization and approaches to hazard assessment.
    Gebel T; Foth H; Damm G; Freyberger A; Kramer PJ; Lilienblum W; Röhl C; Schupp T; Weiss C; Wollin KM; Hengstler JG
    Arch Toxicol; 2014 Dec; 88(12):2191-211. PubMed ID: 25326817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granular biodurable nanomaterials: No convincing evidence for systemic toxicity.
    Moreno-Horn M; Gebel T
    Crit Rev Toxicol; 2014 Nov; 44(10):849-75. PubMed ID: 25257841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The carcinogenic potential of nanomaterials, their release from products and options for regulating them.
    Becker H; Herzberg F; Schulte A; Kolossa-Gehring M
    Int J Hyg Environ Health; 2011 Jun; 214(3):231-8. PubMed ID: 21168363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles.
    Tsuji JS; Maynard AD; Howard PC; James JT; Lam CW; Warheit DB; Santamaria AB
    Toxicol Sci; 2006 Jan; 89(1):42-50. PubMed ID: 16177233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
    Oberdörster G
    J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop.
    Warheit DB; Borm PJ; Hennes C; Lademann J
    Inhal Toxicol; 2007 Jun; 19(8):631-43. PubMed ID: 17510836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research strategy for evaluation methods of the manufactured nanomaterials in NIHS and importance of the chronic health effects studies].
    Hirose A; Nishimura T; Kanno J
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2009; (127):15-25. PubMed ID: 20306702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hazard identification of inhaled nanomaterials: making use of short-term inhalation studies.
    Klein CL; Wiench K; Wiemann M; Ma-Hock L; van Ravenzwaay B; Landsiedel R
    Arch Toxicol; 2012 Jul; 86(7):1137-51. PubMed ID: 22532024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approach to using mechanism-based structure activity relationship (SAR) analysis to assess human health hazard potential of nanomaterials.
    Lai DY
    Food Chem Toxicol; 2015 Nov; 85():120-6. PubMed ID: 26111809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small difference in carcinogenic potency between GBP nanomaterials and GBP micromaterials.
    Gebel T
    Arch Toxicol; 2012 Jul; 86(7):995-1007. PubMed ID: 22418597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomaterial translocation--the biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs--a review.
    Kermanizadeh A; Balharry D; Wallin H; Loft S; Møller P
    Crit Rev Toxicol; 2015; 45(10):837-72. PubMed ID: 26140391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices.
    Bouwmeester H; Lynch I; Marvin HJ; Dawson KA; Berges M; Braguer D; Byrne HJ; Casey A; Chambers G; Clift MJ; Elia G; Fernandes TF; Fjellsbø LB; Hatto P; Juillerat L; Klein C; Kreyling WG; Nickel C; Riediker M; Stone V
    Nanotoxicology; 2011 Mar; 5(1):1-11. PubMed ID: 21417684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research strategies for safety evaluation of nanomaterials, part II: toxicological and safety evaluation of nanomaterials, current challenges and data needs.
    Holsapple MP; Farland WH; Landry TD; Monteiro-Riviere NA; Carter JM; Walker NJ; Thomas KV
    Toxicol Sci; 2005 Nov; 88(1):12-7. PubMed ID: 16120754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grouping of nanomaterials to read-across hazard endpoints: a review.
    Lamon L; Aschberger K; Asturiol D; Richarz A; Worth A
    Nanotoxicology; 2019 Feb; 13(1):100-118. PubMed ID: 30182776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale of genotoxicity testing of nanomaterials: regulatory requirements and appropriateness of available OECD test guidelines.
    Warheit DB; Donner EM
    Nanotoxicology; 2010 Dec; 4():409-13. PubMed ID: 20925448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grouping of nanomaterials for risk assessment.
    Bolt HM
    Arch Toxicol; 2014 Dec; 88(12):2077-8. PubMed ID: 25413730
    [No Abstract]   [Full Text] [Related]  

  • 17. Pluripotent stem cells: An in vitro model for nanotoxicity assessments.
    Handral HK; Tong HJ; Islam I; Sriram G; Rosa V; Cao T
    J Appl Toxicol; 2016 Oct; 36(10):1250-8. PubMed ID: 27241574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The applicability of chemical alternatives assessment for engineered nanomaterials.
    Hjorth R; Hansen SF; Jacobs M; Tickner J; Ellenbecker M; Baun A
    Integr Environ Assess Manag; 2017 Jan; 13(1):177-187. PubMed ID: 26887668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety of medicinal nanoproducts: new areas of toxicological research].
    Grudziński IP
    Rocz Panstw Zakl Hig; 2011; 62(3):239-46. PubMed ID: 22171512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials.
    Som C; Nowack B; Krug HF; Wick P
    Acc Chem Res; 2013 Mar; 46(3):863-72. PubMed ID: 23110540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.